The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study
Clinical trial NCT06962189 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06962189
- Sponsor
- Zhejiang University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-15
- Primary completion
- 2027-12-31
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.